ArticleThe Journal of antibiotics2026
Novel hydroxamate siderophore isolated from Streptomyces sp. D106 via iron-responsive metabolomic analysis.
Article in The Journal of antibiotics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Siderophores are iron-chelating agents secreted by microorganisms under iron-limiting conditions, and have garnered increasing attention for their diverse biological activities. Guided by an iron-responsive metabolomic analysis, a new hydroxamate siderophore designated terragine H (1) was isolated from the fermentation broth of Streptomyces sp. D106, along with three known congeners legonoxamine D (2), terragine A (3) and legonoxamine A (4). The structure of 1 was elucidated by comprehensive NMR and MS analyses, revealing a linear scaffold characterized by a 4-methylhexanoyl side chain and a terminal succinimide moiety. The complete NMR assignment for legonoxamine D (2) is also reported, providing definitive structural validation for a metabolite previously characterized only by MS data. Bioassays revealed that all compounds possess iron-chelating capacity in the chrome azurol S assay, with 3 and 4 showing potency comparable to the clinical standard deferoxamine B. Compounds 1-3 also demonstrated significant antioxidant activity in the DPPH radical scavenging assay. Furthermore, compounds 1 and 3 exhibited moderate cytotoxicity against the MCF-7 tumor cell line.
Indexed as
Identifiers
42191849What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.